Detection of the Atherosclerotic PCSK9 gene Inhibitors Through in silico Method to Improve Targeted Therapy

The PCSK9 is one of the most important marks for evolution therapeutic agents atherosclerosis because its interaction with low-density lipoprotein receptors causes atherosclerosis. Protein-ligand interactions help us to understand true mechanism pharmacological action. This study seeks identify powerful suppression options PCSK9. Initially, reported ACE inhibitors were included in pharmacophore modeling using PharmaGist. Next, ZINCPHARMER was used screen selected model against a ZINC database putative drug candidates docked target protein interactions. 10 best binding energy 9.8-8.2 kcal mol-1 identified by molecular docking and their pharmacokinetic properties oral bioavailability evaluated. (S) severalplant obtained chemicals have been discovered, including anti-hypersensitive drugs such as “Canadine, Hesperetin, Labetalol”. According Biochemistry, these compounds formed stable “protein-ligand” complex. canadine complex had lowest RMSD stable. Future vitro studies could canadin promising inhibitor novel inhibitors.